Free Trial
NYSE:MBX

MBX Biosciences (MBX) Stock Price, News & Analysis

MBX Biosciences logo
$22.46
-0.44 (-1.92%)
(As of 11/1/2024 ET)

About MBX Biosciences Stock (NYSE:MBX)

Key Stats

Today's Range
$22.39
$23.71
50-Day Range
N/A
52-Week Range
$19.33
$26.19
Volume
39,060 shs
Average Volume
129,996 shs
Market Capitalization
$715.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.25
Consensus Rating
Buy

Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

MBX Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
48th Percentile Overall Score

MBX MarketRank™: 

MBX Biosciences scored higher than 48% of companies evaluated by MarketBeat, and ranked 624th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MBX Biosciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about MBX Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for MBX Biosciences are expected to grow in the coming year, from ($13.17) to ($2.26) per share.

  • Short Interest

    There is no current short interest data available for MBX.
  • Dividend Yield

    MBX Biosciences does not currently pay a dividend.

  • Dividend Growth

    MBX Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MBX.
  • News Sentiment

    MBX Biosciences has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for MBX Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for MBX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MBX Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,000,000.00 in company stock and sold $0.00 in company stock.

  • Read more about MBX Biosciences' insider trading history.
Receive MBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter.

MBX Stock News Headlines

Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
See More Headlines

MBX Stock Analysis - Frequently Asked Questions

MBX Biosciences' stock was trading at $21.00 on January 1st, 2024. Since then, MBX stock has increased by 7.0% and is now trading at $22.46.
View the best growth stocks for 2024 here
.

MBX Biosciences (MBX) raised $163 million in an initial public offering on Friday, September 13th 2024. The company issued 10,200,000 shares at $16.00 per share.

MBX Biosciences' quiet period expired on Wednesday, October 23rd. MBX Biosciences had issued 10,200,000 shares in its initial public offering on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. During MBX Biosciences' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.25
High Stock Price Target
$44.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+65.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$715.44 million
Optionable
N/A
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NYSE:MBX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners